- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00228891
Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus
Effects of Pulsatile Insulin Delivery on Peripheral Diabetic Neuropathy
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Diabetic neuropathy (DN) is a progressive complication causing serious problems in 25%-40% of diabetic patients. Significant complications produce painful peripheral dysesthesias, loss of sensation, and gastroparesis. DN may affect the peripheral motor and sensory nerves in addition to the autonomic nervous system (1-3). Treatment strategies for patients with DN have generally concentrated on pain relief, without addressing the underlying pathophysiology of the disease (4). Anecdotal reports from patients treated with pulsatile insulin for other complications suggest that this treatment may show efficacy in patients with DN. This study is designed to compare patients with DN who receive pulsatile insulin with a control group.
Pulses of IV insulin encourages the glucose metabolism in diabetics to normalize in multiple organs, especially muscle, retina, liver, kidney and nerve endings. The process fundamentally requires the administration of high dose insulin pulses similar to those found in non diabetic humans by their pancreas into the surrounding portal circulation. Oral carbohydrates are given simultaneously to augment the process and prevent hypoglycemia. The process is monitored by frequent measuring of glucose levels and respiratory quotients (RQ). RQ is measured by a metabolic cart which determines the ratio VCO2/ VO2. This ratio is specific for the fuel used at any one time by the body. The glucose levels are monitored to keep glucose levels appropriate and the RQ determines the need to readjust the infusion protocol in each patient for subsequent insulin infusion sessions. The insulin pulses are delivered over 1-hour periods with a 1-hour rest period between each session. Three treatments are given during each treatment day.
The respiratory quotient (RQ) is a measurement of CO2 exhaled and O2 inhaled and is proportionate to the fuel sources being used by the body, primarily the liver over short periods of time. The higher the RQ, the more glucose and less alternative fuel sources are being utilized. Following the RQ change helps determine the effectiveness of physiological insulin administration in increasing anabolic functions in diabetic individuals. By improving the body's glucose metabolism and thereby causing beneficial effects of anabolic factors, the possibility of serious complications can be decreased. In addition the use of oral carbohydrate at the same time along with the physiologic insulin administration stimulates the appropriate gut hormones which augment this effect, a response which cannot be duplicated with intravenous glucose. The purpose of our studies is to determine whether the physiologic administration of insulin along with the augmenting effect of oral carbohydrates will normalize metabolism in diabetic patients and correlate with an improvement in their manifestations of diabetic neuropathy.
The RQ is determined by the use of a metabolic cart. Individuals breathe into a mask for 3-5 minutes after a rest period of 30 or more minutes. The ratio of exhaled volume of CO2 to the inhaled volume of O2 is determined as the RQ. The physiologic range is 0.7 to1.3. Individuals using fat as a primary fuel have a ratio of 0.7, protein or mixed fuels is 0.8-0.9 and carbohydrate is 0.9-1.0. Those taking excessive calories will have RQ's higher than 1.05.
- Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH, Vascular Risk factors and Diabetic Neuropathy N Engl J Med 352:341-50, 2005.
- Neuropathy Trust, Diabetic Neuropathy:Prevalence, www.neurocentre.com.
- Potter PJ, Maryniak O, Yamorski R, Jones IC, Incidence of Peripheral Neuropathy in the Contralateral Limb of Persons with Unilateral Amputation due to Diabetes, Journal of Rehabilitation Research and Development 35:335-39, 1998.
- Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengan , Duloxetine versus Placebo in Patients with Painful Diabetic Neuropathy, Pain 116:109-18, 2005.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studie Locaties
-
-
Florida
-
Boca Raton, Florida, Verenigde Staten, 33431
- Florida Atlantic University Center for Complex Systems and Brain Sciences
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- The researchers will include up to 500 patients both male and female between the ages of 20 and 90 diagnosed with type 1 or type 2 diabetes mellitus.
- All patients were diagnosed by their endocrinologists as having diabetic neuropathy
- All patients had failed conventional treatment for diabetic neuropathy
- Taking oral agents and/or insulin for diabetic control
- Under an Endocrinologists supervision for their diabetes management. Endocrinologist must assess and approve patient for participation in this study
- Ability to swallow without difficulty
- Ability to commit to the weekly time requirements associated with the study
Exclusion Criteria:
- Other causes of complications not related to diabetes
- Lack of intravenous access
- Pregnancy
- Alcohol abuse, drug addiction or the use of illegal drugs
- Positive HIV
- Inability to breathe into machine for respiratory quotients
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: 2
Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
|
Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis.
Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
Andere namen:
|
Placebo-vergelijker: 1
Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
|
Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Measure the stabilization or reduction of the decline of diabetic neuropathy by pt questionnaires and diagnostic tests
Tijdsspanne: Measure the stabilization and reduction of complications associated with diabetic neuropathy
|
Measure the stabilization and reduction of complications associated with diabetic neuropathy
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Betty Tuller, PhD, Florida Atlantic University
Publicaties en nuttige links
Algemene publicaties
- Gill G, Moulik P. Mortality and diabetic neuropathy. Diabet Med. 2005 Sep;22(9):1289. doi: 10.1111/j.1464-5491.2005.01729.x. No abstract available.
- Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006 Jul;108(5):477-81. doi: 10.1016/j.clineuro.2005.08.003. Epub 2005 Sep 16.
- Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 Jan 27;352(4):341-50. doi: 10.1056/NEJMoa032782.
- Potter PJ, Maryniak O, Yaworski R, Jones IC. Incidence of peripheral neuropathy in the contralateral limb of persons with unilateral amputation due to diabetes. J Rehabil Res Dev. 1998 Jul;35(3):335-9.
- Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005 Jul;116(1-2):109-18. doi: 10.1016/j.pain.2005.03.029.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Glucosemetabolismestoornissen
- Metabole ziekten
- Ziekten van het zenuwstelsel
- Endocriene systeemziekten
- Diabetes complicaties
- Neuromusculaire aandoeningen
- Ziekten van het perifere zenuwstelsel
- Suikerziekte
- Diabetische neuropathieën
- Hypoglycemische middelen
- Fysiologische effecten van medicijnen
- Insuline
- Insuline, Globin Zink
Andere studie-ID-nummers
- H09-66 NEU1
- MH42900 and MH01386 (NIMH)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes Mellitus, Met Complicaties
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetestype1 | Diabetes mellitus type 1 | Auto-immuun diabetes | Diabetes Mellitus, insulineafhankelijk | Jeugddiabetes | Diabetes, auto-immuunziekte | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | Diabetes Mellitus,... en andere voorwaardenVerenigde Staten
-
Medical College of WisconsinMedical University of South CarolinaVoltooidSuikerziekte | Diabetes mellitus type 2 | Diabetes Mellitus bij volwassenen | Niet-insulineafhankelijke diabetes mellitus | Niet-insulineafhankelijke diabetes mellitus, type IIVerenigde Staten
-
Guang NingWervingDiabetes mellitus type 2 | Diabetes mellitus type 1 | Monogene diabetes | Pancreatogene diabetes | Door medicijnen veroorzaakte diabetes mellitus | Andere vormen van diabetes mellitusChina
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
Meir Medical CenterVoltooidDiabetes mellitus type 2 | Diabetes Mellitus, niet-insulineafhankelijk | Diabetes Mellitus, over orale hypoglycemische behandeling | Diabetes Mellitus bij volwassenenIsraël
-
Peking Union Medical College HospitalOnbekendDiabetes mellitus type 2 | Diabetes mellitus type 1 | Zwangerschapsdiabetes mellitus | Pancreatogene diabetes mellitus | Pregestationele diabetes mellitus | Diabetespatiënten in de perioperatieve periodeChina
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Actief, niet wervendDiabetes mellitus, type 2 | Diabetes mellitus, Type II | Diabetes Mellitus, aanvang op volwassen leeftijd | Diabetes Mellitus, niet-insulineafhankelijk | Diabetes Mellitus, niet-insuline-afhankelijkVerenigde Staten
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)VoltooidDiabetes mellitus, type 2 | Diabetes mellitus, Type II | Diabetes Mellitus, aanvang op volwassen leeftijd | Diabetes Mellitus, niet-insulineafhankelijk | Diabetes Mellitus, niet-insuline-afhankelijkVerenigde Staten
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)VoltooidDiabetes mellitus, type 2 | Diabetes mellitus, Type II | Diabetes Mellitus, aanvang op volwassen leeftijd | Diabetes Mellitus, niet-insulineafhankelijk | Diabetes Mellitus, niet-insuline-afhankelijkVerenigde Staten
-
Hoffmann-La RocheRoche DiagnosticsVoltooidDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Duitsland